Kuros Biosurgery AG We are a biotechnology company dedicated to developing biomaterials and bioactive biomaterial combination products for indications in trauma, wound and spine. Our products are based on two different matrix technologies that allow the attachment of biologics or drugs and that can be applied locally. One of these two matrices is Fibrin, a natural biomaterial that is the main component of blood clots and that is well-proven in surgical applications. Several products based on Fibrin are currently in clinical trials. Our other matrix technology is a synthetic matrix that allows a high degree of tailoring of our physical characteristics, e.g. elasticity, strength and rate of biodegradation. Products based on synthetic matrices for various indications are at several stages of development. We hold proprietary technologies for the incorporation of biologics and other bioactives into these matrixes. For example, using one of these technologies, incorporation is based on covalent binding by a linker. Upon exposure to enzymes of the patient’s own cells in the natural healing process the linker can be cleaved, therewith allowing a gradual release based on “cellular demand”. With currently approximately 55 employees and more than 13 product candidates in the pipeline we show an ongoing interest in partnering, in- or out-licensing and collaboration opportunities.